0001193125-26-193315
SEC filingQ1 losses widened substantially to -$158.3M as Viking Therapeutics advanced its clinical pipeline for metabolic disorders, reflecting heightened investment in development programs amid zero revenue.
Viking Therapeutics, a clinical-stage biopharmaceutical company, reported escalating losses in Q1 FY2026, with operating income at -$164.1 million, a 195.9% worsening from -$55.5 million in the prior year quarter. This reflects the company's focus on developing novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, where it has incurred losses and negative cash flows from operations since inception, with no revenues generated.
Net income stood at -$158.3 million, deteriorating 247.0% from -$45.6 million year-over-year, driven by ongoing investments in drug candidates like VK2735, which is being developed in both oral and subcutaneous formulations for potential treatment of metabolic disorders such as obesity. Diluted EPS was -$1.37, down 234.1% from -$0.41, underscoring the financial impact of these clinical-stage activities.
Looking ahead, Viking anticipates continued losses for the foreseeable future, expected to increase materially as it advances development, seeks regulatory approvals, and pursues commercialization of drug candidates. Uncertainties persist around potential collaborations, their timing, and impact on development plans and capital needs, highlighting the inherent risks in clinical-stage biopharma operations.